csl-111 Search Results


csl-111  (CSL Behring)
90
CSL Behring csl-111
Csl 111, supplied by CSL Behring, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/csl-111/product/CSL Behring
Average 90 stars, based on 1 article reviews
csl-111 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
recombinant hdl mimetics csl-111  (Mimetics)
90
Mimetics recombinant hdl mimetics csl-111
Recombinant Hdl Mimetics Csl 111, supplied by Mimetics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/recombinant hdl mimetics csl-111/product/Mimetics
Average 90 stars, based on 1 article reviews
recombinant hdl mimetics csl-111 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
rhdl csl-111 (csl ltd, parkville, australia)  (CSL Limited)
90
CSL Limited rhdl csl-111 (csl ltd, parkville, australia)
The CD34 + progenitor cells (A and B) and CD34 + /KDR + endothelial progenitor cells (C and D) were quantified in blood samples collected at baseline and at follow-up. The follow-up samples for the <t>CSL-111-treated</t> group were obtained 16 ± 4 days following completion of the 4 weekly rHDL infusions. Each box plot in A and C shows the median, the interquartile range, the maximum and the minimum of the relative change. B and D show absolute numbers of CD34 + (B) and CD34 + /KDR + (D) endothelial progenitor cell count at baseline and at follow-up. p < 0.05 between groups (A and B), p = N.S. (C and D) from Mann-Whitney tests.* one outlier (baseline cell count 1.6/μl, follow-up 0.1/μl) not presented in figure due to axis limits.
Rhdl Csl 111 (Csl Ltd, Parkville, Australia), supplied by CSL Limited, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rhdl csl-111 (csl ltd, parkville, australia)/product/CSL Limited
Average 90 stars, based on 1 article reviews
rhdl csl-111 (csl ltd, parkville, australia) - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


The CD34 + progenitor cells (A and B) and CD34 + /KDR + endothelial progenitor cells (C and D) were quantified in blood samples collected at baseline and at follow-up. The follow-up samples for the CSL-111-treated group were obtained 16 ± 4 days following completion of the 4 weekly rHDL infusions. Each box plot in A and C shows the median, the interquartile range, the maximum and the minimum of the relative change. B and D show absolute numbers of CD34 + (B) and CD34 + /KDR + (D) endothelial progenitor cell count at baseline and at follow-up. p < 0.05 between groups (A and B), p = N.S. (C and D) from Mann-Whitney tests.* one outlier (baseline cell count 1.6/μl, follow-up 0.1/μl) not presented in figure due to axis limits.

Journal: PLoS ONE

Article Title: Beneficial Effects of Reconstituted High-Density Lipoprotein (rHDL) on Circulating CD34 + Cells in Patients after an Acute Coronary Syndrome

doi: 10.1371/journal.pone.0168448

Figure Lengend Snippet: The CD34 + progenitor cells (A and B) and CD34 + /KDR + endothelial progenitor cells (C and D) were quantified in blood samples collected at baseline and at follow-up. The follow-up samples for the CSL-111-treated group were obtained 16 ± 4 days following completion of the 4 weekly rHDL infusions. Each box plot in A and C shows the median, the interquartile range, the maximum and the minimum of the relative change. B and D show absolute numbers of CD34 + (B) and CD34 + /KDR + (D) endothelial progenitor cell count at baseline and at follow-up. p < 0.05 between groups (A and B), p = N.S. (C and D) from Mann-Whitney tests.* one outlier (baseline cell count 1.6/μl, follow-up 0.1/μl) not presented in figure due to axis limits.

Article Snippet: Briefly, ERASE was a randomized, double-blind, placebo-controlled, multicentre trial which evaluated the effects of the rHDL CSL-111 (CSL Ltd, Parkville, Australia) on plaque burden as assessed by intravascular ultrasonography in patients who were recruited within 2 weeks of an ACS, defined as unstable angina, non-ST-segment elevation myocardial infarction (MI) or ST-segment elevation MI.

Techniques: Cell Counting, MANN-WHITNEY

Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors (n = 7) and plated on fibronectin-coated plates in the absence or presence of CSL-111 (1 mg/mL) from day 0 to day 4 (D0-4), 4 to 7 (D4-7) or 0 to 7 (D0-7). After 7 days of culture, adherent cells were harvested and analyzed by flow cytometry. (A) All adherent cells were quantified by flow cytometry using cell counting beads for enumeration. (B) CSL-111 treatment increases the total number of CD34 + cells when added to cell culture media at D0-4 and D0-7; CD34 + cells were quantified by flow cytometry. (C) CSL-111 treatment reduces basal apoptosis in eEPCs when added to cell culture media at D0-4 and D0-7. Apoptosis was measured by flow cytometry using Annexin V labeling. Each box plot shows the median, the interquartile range, the maximum and the minimum of the relative change. * indicates p < 0.05 between groups from Wilcoxon signed-rank tests.

Journal: PLoS ONE

Article Title: Beneficial Effects of Reconstituted High-Density Lipoprotein (rHDL) on Circulating CD34 + Cells in Patients after an Acute Coronary Syndrome

doi: 10.1371/journal.pone.0168448

Figure Lengend Snippet: Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors (n = 7) and plated on fibronectin-coated plates in the absence or presence of CSL-111 (1 mg/mL) from day 0 to day 4 (D0-4), 4 to 7 (D4-7) or 0 to 7 (D0-7). After 7 days of culture, adherent cells were harvested and analyzed by flow cytometry. (A) All adherent cells were quantified by flow cytometry using cell counting beads for enumeration. (B) CSL-111 treatment increases the total number of CD34 + cells when added to cell culture media at D0-4 and D0-7; CD34 + cells were quantified by flow cytometry. (C) CSL-111 treatment reduces basal apoptosis in eEPCs when added to cell culture media at D0-4 and D0-7. Apoptosis was measured by flow cytometry using Annexin V labeling. Each box plot shows the median, the interquartile range, the maximum and the minimum of the relative change. * indicates p < 0.05 between groups from Wilcoxon signed-rank tests.

Article Snippet: Briefly, ERASE was a randomized, double-blind, placebo-controlled, multicentre trial which evaluated the effects of the rHDL CSL-111 (CSL Ltd, Parkville, Australia) on plaque burden as assessed by intravascular ultrasonography in patients who were recruited within 2 weeks of an ACS, defined as unstable angina, non-ST-segment elevation myocardial infarction (MI) or ST-segment elevation MI.

Techniques: Isolation, Flow Cytometry, Cell Counting, Cell Culture, Labeling

Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors (n = 3) and plated on fibronectin-coated plates in the absence or presence of CSL-111 (1 mg/mL) from day 0 to day 4 (D0-4), 4 to 7 (D4-7) or 0 to 7 (D0-7). On day 7 of culture, adherent cells were harvested and assayed in a modified Boyden chamber for their capacity to migrate along an SDF-1 gradient. Significantly increased migration was observed among cells treated with CSL-111 for day 0 to day 4 (**; p = 0.0003) and 0 to 7 (*; p = 0.0135) compared to controls. Figure shows adjusted mean±standard error of the mean (SEM). p-values are reported from mixed model ANOVA.

Journal: PLoS ONE

Article Title: Beneficial Effects of Reconstituted High-Density Lipoprotein (rHDL) on Circulating CD34 + Cells in Patients after an Acute Coronary Syndrome

doi: 10.1371/journal.pone.0168448

Figure Lengend Snippet: Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donors (n = 3) and plated on fibronectin-coated plates in the absence or presence of CSL-111 (1 mg/mL) from day 0 to day 4 (D0-4), 4 to 7 (D4-7) or 0 to 7 (D0-7). On day 7 of culture, adherent cells were harvested and assayed in a modified Boyden chamber for their capacity to migrate along an SDF-1 gradient. Significantly increased migration was observed among cells treated with CSL-111 for day 0 to day 4 (**; p = 0.0003) and 0 to 7 (*; p = 0.0135) compared to controls. Figure shows adjusted mean±standard error of the mean (SEM). p-values are reported from mixed model ANOVA.

Article Snippet: Briefly, ERASE was a randomized, double-blind, placebo-controlled, multicentre trial which evaluated the effects of the rHDL CSL-111 (CSL Ltd, Parkville, Australia) on plaque burden as assessed by intravascular ultrasonography in patients who were recruited within 2 weeks of an ACS, defined as unstable angina, non-ST-segment elevation myocardial infarction (MI) or ST-segment elevation MI.

Techniques: Isolation, Modification, Migration